YOUR ROLE IS CRITICAL FOR VACCINATING THE ~133 MILLION ADULTS NOW ELIGIBLE FOR VACCINATION1,*

The CDC has published an updated recommendation for hepatitis B vaccination: all adults aged 19-59 should be vaccinated2,†

HEPATITIS B VACCINES ARE LIKELY TO BECOME THE SECOND MOST WIDELY USED ADULT VACCINES IN YOUR HEALTHCARE SYSTEM1

How many adults are eligible for vaccination in 2022?1,*

Approximately 133 million adults are eligible for hepatitis B vaccination[3,†] Approximately 133 million adults are eligible for hepatitis B vaccination[3,†]

Series completion is more important than ever2,3

3-DOSE ADULT HEPATITIS B VACCINES MAY CREATE CHALLENGES FOR IMMUNIZATION PROGRAMS3

In a study, approximately 75% of adults aged 19+ did not receive all 3 doses of hepatitis B vaccines[5]

IN A STUDY of adults aged 19+ did not receive all 3 doses4

Failed series completion can leave patients unprotected and create inefficiencies for health systems3,5

Most patients do not achieve protective immunity without hepatitis B series completion and increased number of patients will compound operational inefficiencies with 3-dose vaccines[1,2,4,7] Most patients do not achieve protective immunity without hepatitis B series completion and increased number of patients will compound operational inefficiencies with 3-dose vaccines[1,2,4,7]

Adults eligible for influenza vaccines calculated from population aged 18+ in 2022; adults eligible for shingles vaccines calculated using adults turning 50 years old in 2022, adults aged >50 who are unvaccinated based on CDC coverage rates, and immunocompromised adults aged 19-49; adults eligible for pneumonia vaccines included adults aged 65+ and at-risk adults aged 18-64 excluding smokers, patients with chronic heart disease, and patients who are immunocompromised; adults eligible for hepatitis B vaccination calculated using US census data published in 2018, CDC coverage data, and risk factor analyses.1

The CDC also recommends hepatitis B vaccination for adults aged ≥60 with hepatitis B risk factors. Adults aged ≥60 without risk factors may receive hepatitis B vaccination.2

2-dose HEPLISAV-B protects patients faster8,9

DISCOVER MORE EFFICIENT VACCINATION
 

Important Safety Information

INDICATION

HEPLISAV-B is indicated for prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older.

IMPORTANT SAFETY INFORMATION

Do not administer HEPLISAV-B to individuals with a history of severe allergic reaction (e.g., anaphylaxis) after a previous dose of any hepatitis B vaccine or to any component of HEPLISAV-B, including yeast.

Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of HEPLISAV-B.

Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to HEPLISAV-B.

Hepatitis B has a long incubation period. HEPLISAV-B may not prevent hepatitis B infection in individuals who have an unrecognized hepatitis B infection at the time of vaccine administration.

The most common patient-reported adverse reactions reported within 7 days of vaccination were injection site pain (23%-39%), fatigue (11%-17%), and headache (8%-17%).

References: 1. Data on file. Dynavax Technologies Corporation; 2022. 2. Centers for Disease Control and Prevention. Recommended adult immunization schedule for ages 19 years or older, United States, 2022. Accessed May 18, 2022. https://www.cdc.gov/vaccines/schedules/downloads/adult/adult-combined-schedule.pdf 3. Nelson JC, Bittner RC, Bounds L, et al. Compliance with multiple-dose vaccine schedules among older children, adolescents, and adults: results from a vaccine safety datalink study. Am J Public Health. 2009;99(suppl 2):S389-S397. doi:10.2105/AJPH.2008.151332 4. Williams WW, Lu PJ, O’Halloran A, et al. Surveillance of vaccination coverage among adult populations—United States, 2015. MMWR Surveill Summ. 2017;66(11):1-28. doi:10.15585/mmwr.ss6611a1 5. Mast EE, Weinbaum CM, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep. 2006;55(RR-16):1-33. 6. Dynavax Technologies Corporation. FDA Advisory Committee Briefing Document: HEPLISAV-B™ (Hepatitis B Vaccine [Recombinant], Adjuvanted). Presented at: Meeting of the Vaccines and Related Biological Products Advisory Committee; July 28, 2017; Silver Spring, MD. 7. Freedman M, Kroger A, Hunter P, Ault KA. Recommended adult immunization schedule, United States, 2020. Ann Intern Med. 2020;172(5):337-347. doi:10.7326/M20-0046 8. HEPLISAV-B [package insert]. Emeryville, CA: Dynavax Technologies Corporation; 2020. 9. Engerix-B [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2018.

See the CDC recommendation

INDICATION

HEPLISAV-B is indicated for prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older.

IMPORTANT SAFETY INFORMATION

Do not administer HEPLISAV-B to individuals with a history of severe allergic reaction (e.g., anaphylaxis) after a previous dose of any hepatitis B vaccine or to any component of HEPLISAV-B, including yeast.